Objective. Data about the survival rate of lupus patients on dialysis is controversial. The objective of this controlled prospective study was to report the survival of SLE patients undergoing dialysis and to analyse factors associated with mortality.
Introduction
Despite improvement in the overall survival of SLE patients, 1025% of patients will have a fatal outcome in 10 years [1] . LN is one of the most severe manifestations of SLE and 1020% of these patients will progress to end-stage renal disease (ESRD) [2] . Changes in this figure can be expected in coming years because of the emergence of more effective and less toxic treatments, as pointed out in a recent review [3] . It is common practice to withdraw immunosuppressive therapy when SLE patients reach ESRD, but recent data have indicated that the burnout phenomenon could be a misconception [46] . This subject was the basis for an extensive review [7] . Researchers diverge about the survival rate of lupus patients on dialysis in comparison with the general dialysis population, with some finding no difference [5, 8] and others a worse prognosis [4, 9] . The present study aimed to report the 5-year survival of SLE patients undergoing dialysis in comparison with a control group well matched for gender, age, dialysis modality, dialysis vintage and HCV serology, and analyse factors associated with mortality.
Patients and methods
Between May 2003 and February 2004, 20 dialysis centres in six districts of the metropolitan area of Rio de Janeiro, Brazil, were visited for this prospective study. They accounted for $30% of the dialysis centres and 50% of the dialysis patients in the state (3535 patients).
Kidney transplant patients were not included. Approval of each participant institution was obtained and the study was approved by the ethical committee of the Medical School of the Universidade Federal Fluminense under the number 12/03. Informed consent was obtained from all patients. Cases with <6 months of dialysis were excluded to account for the risk of spontaneous recovery of renal function and precocious death. A control group was assembled for simultaneous prospective follow-up comprising dialysis patients without SLE, matched for five variables: gender, age, dialysis modality, dialysis vintage (time on dialysis) and dialysis-associated HCV infection. HIV infection, diabetes mellitus, systemic vasculitis and other autoimmune diseases were used as exclusion criteria.
Haemodialysis (HD) sessions were accomplished with proportional mixture machines with an ultrafiltration control device, blood flow of 300450 ml/min, bicarbonatebuffered dialysate (Ca = 2.53.5 mEq/l) at 500 ml/min and cellulose acetate or polysulphone hollow-fibre dialysers. Reverse osmosis systems were used to provide water treatment. Dialysers were reprocessed with peracetic acid as the sterilant and discarded after the 12th reuse or at any moment if the internal volume of the hollow fibres decreased by more than 20%. Other cleaning agents were not used.
A clinical evaluation was made at each centre by the time of entrance to the study. Before the dialysis sessions, a blood sample was collected for analyses that included CRP, b2-microglobulin, creatinine, anti-dsDNA, C3 and C4, and aCL IgG. Patients were followed during 60 months under management of their assistant physicians. The end point was death of any cause. All-cause mortality was compared between groups.
Disease activity was evaluated using the SLEDAI, without the renal-related parameters [non-renal (nr)SLEDAI] [4, 5, 10, 11] . Assessment of organ damage was made using the SLICC/ACR Damage Index, in which damage was defined as irreversible impairment present after SLE diagnosis and persistent for at least 6 months [12].
Statistical analysis
Results were expressed as mean and S.D. if numbers had a normal distribution or, alternatively, as median and range. To analyse differences between groups, unpaired t-test or its non-parametric equivalent, the MannWhitney U-test, was used. Frequencies were compared using 2 or
Fisher's exact test. Estimates of survival were studied by life table analysis using the KaplanMeier method with log rank. Associations of risk factors with mortality were tested with the Cox proportional hazards model. Receiver operating characteristic (ROC) curves were used to detect cut-off values for continuous variables associated with mortality by calculating the Youden index (highest sum of sensitivity and the specificity À1).
Effective inclusion of the variable in the multivariate model required a high probability of association with mortality in the univariate analysis (P < 0.10). P < 0.05 was considered significant. Analyses were performed using SPSS for Windows version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Of 3535 ESRD patients, 63 (1.8%) met the ACR criteria for SLE. After application of the exclusion criteria, 57 patients remained in the study. Fifty-six patients were in HD and one was treated by continuous ambulatory peritoneal dialysis. The general features of the SLE patients and controls are shown in Table 1 . The preponderant gender was female (95%) and the distribution of the races in the two groups was comparable. Values of mean urea reduction ratio (URR) denote similar and adequate dialysis for both groups [75 (9%) vs 74 (13%), P = 0.248]. The group of SLE tended to have a slightly shorter time on dialysis [54 (50) vs 71 (53) months, P = 0.0829). Twelve (21%) patients in each group had dialysis-acquired HCV infection. In the control group, essential arterial hypertension was the cause of ESRD in 32 (56.1%) patients, followed for idiopathic chronic GN in 14 (24.6%), chronic pyelonephritis in 6 (10.5%), polycystic kidney disease in 4 (7%) and preeclampsia in 1 (1.8%) patient. By the time of the examination for admission, clinical manifestations were arthritis, myositis, alopecia, malar rash, cutaneous vasculitis and oral ulcers. The most frequent laboratory abnormalities were low complement levels and positivity for anti-DNA antibodies. As usual, none of the patients with dialysis-acquired HCV infection had findings of cryoglobulinaemia (peripheral neuropathy or palpable purpura).
As a whole, 30 patients were on medication for SLE. Twenty-nine were on prednisone, 10 of whom received 520 mg/day. In 5 of these 10 patients, a second drug was associated with prednisone (chloroquine/HCQ in 4 and thalidomide in 1). Among those on 410 mg/day of prednisone, four were also on chloroquine/HCQ and two on AZA. One patient was on triple therapy (prednisone, AZA and chloroquine/HCQ). Chloroquine was the only medication in one case. None of the patients was on a dose between 10 and 20 mg prednisone/day. None of the patients with dialysis-acquired HCV infection were treated with IFN or ribavirin. The only anti-coagulation used for SLE and control patients was the one needed for the dialysis treatment. None of the patients had a diagnosis of secondary APS.
During the 60 months of follow-up, only one control was lost, whereas eight patients in each group underwent kidney transplantation (data censored). The mean observation period for SLE patients and controls was 44.4 (20.4) and 46.9 (20.9) months, respectively. At the end of 5 years of follow-up there were 17 deaths in the SLE group and 9 in the control group. Cardiovascular disease was the main cause of death in the SLE group, eight cases, followed by infection, three cases. In 2 of these 11 patients, lupus activity was diagnosed shortly before the fatal Censored data are indicated by short bars crossing the curve line.
a Number entering the interval.
event. Of the six remaining deaths, one was accidental (trauma), one due to disseminated ovarian cancer and in four the cause was unknown. In the control group, deaths were due to cardiovascular diseases in six patients and in three patients the cause could not be determined. The KaplanMeier curves for cumulative survival of SLE patients and controls are shown in Fig. 1 . A trend for a lower cumulative survival in SLE patients can be observed but statistical significance was not found (67% vs 83%, P = 0.096).
Factors associated with mortality in SLE patients were analysed in a Cox proportional hazard model. In the univariate analysis model, the following variables were tested: age at entrance, gender, SLE duration, dialysis vintage, SLICC, immunosuppressive use, nrSLEDAI (as a continuous variable), serum levels of creatinine, calcium, phosphorus, CRP, b2-microglobulin, aCL IgG >40 GPL, calcium/phosphorus product, URR and positivity for anti-HCV (Table 2) . In this univariate analysis, only nrSLEDAI [hazard ratio (HR) 1.176; 95% CI 1.043, 1.326; P = 0.008], immunosuppressant use (HR 2.713; 95% CI 1.032, 7.133, P = 0.043) and URR (HR 0.967; 95% CI 0.930, 1.005; P = 0.086) were found to be significantly associated with mortality.
An ROC curve was obtained to better analyse the association of the nrSLEDAI score with mortality in SLE patients. The area under the curve was 0.693 and the calculated Youden index suggested that an nrSLEDAI value >8 was positively associated with mortality.
The multivariate analysis included variables with a high probability of association with mortality (P < 0.05 in the univariate analysis): nrSLEDAI, now as a categorical variable (nrSLEDAI > 8), immunosuppressive agent use and URR (Table 3) . Only nrSLEDAI > 8 (HR 6.368; 95% CI 1.798, 22.548; P = 0.004) and URR (HR 0.953; 95% CI 0.917, 0.990; P = 0.014) were confirmed as independent factors associated with mortality in lupus patients.
KaplanMeier curves of SLE patients, factored by nrSLEDAI > 8, were again compared with that of non-SLE patients (Fig. 2) . A statistically significant difference was found between the three curves (P < 0.001). When each pair of curves was separately analysed, cumulative survival was significantly lower (P < 0.001) in patients with nrSLEDAI > 8 (17%) in comparison with either non-SLE patients (83%) or SLE patients with nrSLEDAI 4 8 (73%). Survival between controls and SLE patients with nrSLEDAI 4 8 were not different (P = 0.351).
Discussion
Abatement of lupus activity after disease progression to ESRD is controversial, with authors more recently arguing the withdrawal of immunosuppressant agents after dialysis start [6, 13] . Interestingly, most of the studies have shown persistent lupus activity in patients on dialysis [46] , allowing us to question whether improvements in dialysis treatment may have contributed to restoration of immunocompetence of SLE patients.
As a whole, the studies addressing survival of SLE patients on dialysis either do not have a control group or the selection of this group is subject to criticism. Such inadequacy was pointed out in a recent review discussing this subject [14] . To properly address this issue, we selected 57 SLE patients and 57 non-SLE patients, well matched for age, gender, dialysis modality, time on dialysis and positive serology for HCV infection as a group for comparison with SLE patients. It should be noted that the high incidence of dialysis-associated HCV in our cohort is indeed a reflection of the elevated prevalence of such infection in the dialysis population in Brazil [15] . More importantly, we assessed the activity of disease in SLE patients at entrance to evaluate its impact on survival.
In the present study, a clear trend to lower survival in the SLE group as a whole compared with controls was found for the 60-month follow-up period, but a statistically significant difference was not reached (67% vs 83%, P = 0.096). In a Chinese retrospective study, SLE and age-matched non-SLE dialysis patients with a mean age of 38 years were compared [4] . The 5-year survival rate was significantly lower in the SLE group (73% vs 95%, www.rheumatology.oxfordjournals.org P < 0.05). The presence of the control group matched for age and duration of dialysis reduces the survival bias. The causes of death in SLE and non-SLE patients also diverged. Infection was more prevalent in lupus patients, with deaths occurring >1 year after dialysis. Finally, in a retrospective study based on chart reviews, mortality in Asiatic ESRD lupus patients exhibited a 26-fold increase compared with the general population [16] . We analysed the factors associated with mortality in SLE patients in a univariate analysis and found a positive association for three variables: disease activity (as measured by the nrSLEDAI), immunosuppressive use and URR. Despite previous data implicating the SLICC damage index as a predictor of mortality in SLE patients [17, 18] , findings in this regard were negative in our study. One possible explanation for this finding is that kidney failure, one of the major factors impacting on mortality, was present in every patient of our cohort. Age and gender were not found to be associated with mortality but the studied population was essentially composed of female and young subjects, and the absence of association of these variables with overall prognosis did not come as a surprise. Interestingly, data also demonstrated that survival was not affected by any laboratory test.
From the ROC curve, the presence of nrSLEDAI > 8 emerged as a significant predictor for mortality in SLE patients. As a next step, nrSLEDAI > 8, immunosuppressive use and URR values were included in a multivariate model. Here, only the URR and the nrSLEDAI scoring remained as independent factors associated with mortality in lupus patients. The impact of the URR was low but statistically significant. Good dialysis quality, as measured by high values of URR, has been associated with a better prognosis in the general population on dialysis [19] . In contrast, the impact of nrSLEDAI > 8 upon mortality was enormous, increasing the probability of death more than six-fold.
Finally, the KaplanMeier survival curve of SLE patients with nrSLEDAI 48 was very similar to the control group, with survival rates of 73% and 83%, respectively. Impressively, the percentage of fatalities in lupus patients with nrSLEDAI > 8 approached 100% in a way that the survival rate at 5 years of follow-up was only 17% and statistically different from the other two curves. Considering that the studied SLE patients were relatively young, with a mean age of 38 years at entrance, this finding becomes especially relevant.
The SLEDAI has been used as an activity score and also as a marker of mortality in SLE patients not on dialysis [2022] . In a retrospective study involving a small number of peritoneal dialysis, HD and kidney transplant patients without a control group, higher nrSLEDAI scores were associated with mortality [5] .
It should be noted that the mortality rate among ESRD patients is excessively high and the main cause of death is cardiovascular disease [15, 23] . A form of rapidly progressive arterial disease has been reported in dialysis patients for >30 years [24] and seems to occur at any stage of chronic kidney disease, even before the start of dialysis. Traditional risk factors such as smoking and dyslipidaemia may contribute to this high cardiovascular mortality. However, the impact of non-traditional factors such as mineral disorders, oxidative stress, anaemia and inflammation may prevail in this regard [2528] . Of note, ESRD patients with high levels of CRP have a lower survival rate due to increased overall and cardiovascular mortality [29] .
The bimodal pattern of mortality in SLE patients, which has been reported for a long time [3] , has recently been disputed [30] . The main causes of late mortality in these patients are now thought to be infection [30] and cardiovascular disease (due to an underlying accelerated atherosclerosis). In this setting, inflammation seems to play an important role in the development of arterial disease [19, 20, 31] .
We wonder whether the high mortality rate of relatively young patients with nrSLEDAI >8 is related to the concomitant presence of two conditions clearly linked to inflammation and atherosclerosis. In support of this hypothesis, the nature of death, which was known in four of the five subjects with nrSLEDAI > 8, was uniformly cardiovascular. The impact of immunosuppressive agents upon mortality in our population is less clear. At entrance, only one of the six patients with nrSLEDAI > 8 used AZA (100 mg/day), in combination with 5 mg of prednisone. Of the remaining ones, three used only prednisone (20 mg/ day), and two were not taking any lupus medication. Furthermore, no significant association was found between immunosuppressive use at entrance and mortality in the multivariate analysis. By the time of the death, the information regarding immunosuppressive use was not available.
Our study, prospective and observational, carries some limitations. We dealt with a relatively small number of prevalent patients but it should be pointed out that a sample of 57 SLE patients in a prospective controlled design represents one of the largest series in the literature. It should also be stressed that patients were followed by their assistant physicians. As researchers, we could not interfere in their management. In addition, nrSLEDAI was only scored at entrance in the study. Despite that, we were able to find a strong association of high nrSLEDAI scoring with 5-year mortality in a cohort of well-dialysed young adults with lupus, allowing us to question whether the policy to withdraw immunosuppressive agents in this scenario is appropriate. Whether strict activity control by intensive immunosuppression can result in a reduction in fatalities remains to be determined.
Rheumatology key message
. Active lupus patients have low survival in dialysis.
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